edoxaban
Selected indexed studies
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. (N Engl J Med, 2018) [PMID:29231094]
- Edoxaban in cardiovascular disease management: Review. (Br J Clin Pharmacol, 2022) [PMID:34365675]
- Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. (Eur Heart J, 2019) [PMID:30976787]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. (2018) pubmed
- Edoxaban in cardiovascular disease management: Review. (2022) pubmed
- Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. (2019) pubmed
- Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial. (2023) pubmed
- Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. (2019) pubmed
- Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. (2015) pubmed
- Edoxaban Anticoagulation in Atrial Fibrillation: Real-World Data and Evidence. (2023) pubmed
- Edoxaban for the prevention of stroke in patients with atrial fibrillation. (2019) pubmed
- Edoxaban: A direct oral anticoagulant. (2017) pubmed
- Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. (2024) pubmed